1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2015
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2015
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2016-2026 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2015
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2015
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2016-2026
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2014
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2015-2026
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2016-2026
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2016-2026
4.3.2 The PD-1 Inhibitors Submarket Forecast 2016-2026
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2014-2015
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2016-2026
5.2.1 How Will Regional Market Shares Change to 2026?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2016-2026
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Atezolizumab (MPDL3280A/RG7446) – Roche/Genentech
6.1.2 Durvalumab (MEDI4736) – AstraZeneca/MedImmune
6.1.3 Avelumab – (MSB0010718C) – Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) – CureTech Ltd
6.1.5 AMP-224 – GSK/Amplimmune
6.1.6 TSR-042 – TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) – AstraZeneca/MedImmune
6.1.8 REGN2810 – Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) – AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 – Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis/Aurigene
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) – NewLink Genetics
6.6.2.2 NLG919 – NewLink Genetics
6.6.2.3 INCB024360 – Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 – AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market With Similar Products

8. Research Interviews
8.1 Interview with Dr Nicolai Wagtmann, PhD, Chief Scientific Officer, Innate Pharma, Marseille, France
8.1.1 Innate Pharma’s Immunotherapy Portfolio
8.1.2 The Advantages and Mechanisms Used by Checkpoint Inhibitors
8.1.3 The Disadvantages of Checkpoint Inhibitors
8.2 Interview with Dr. Frédéric Triebel, CFO/CSO of Prima Biomed, Founder of Immutep
8.2.1 LAG-3 Inhibitors: An Upcoming Area of Checkpoint Inhibitor Research
8.2.2 Advantages and Disadvantages of LAG-3 Inhibitors on the Checkpoint Inhibitor Market
8.2.3 The Future Direction of the Checkpoint Inhibitor Market for Prima Biomed

9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2026
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

List of Tables
Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2015
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2014
Table 3.9 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2015
Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2014
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2014
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2015
Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2015
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2015-2020
Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2021-2026
Table 4.13 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market, 2015-2026
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2020
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2021-2026
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2014-2019
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020-2026
Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.8 EU5 Market Shares (%), 2014-2019
Table 5.9 EU5 Market Shares (%), 2020-2026
Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.1 Selected Combination Therapies for Atezolizumab, 2015
Table 6.2 Atezolizumab Forecast: Revenue ($bn), 2016-2020
Table 6.3 Atezolizumab Forecast: Revenue ($bn), 2021-2026
Table 6.4 Durvalumab Forecast: Revenue ($bn), 2016-2020
Table 6.5 Durvalumab Forecast: Revenue ($bn), 2021-2026
Table 6.6 Avelumab Forecast: Revenue ($bn), 2017-2020
Table 6.7 Avelumab Forecast: Revenue ($bn), 2021-2026
Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2016-2020
Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2021-2026
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026
Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026

List of Figures
Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2015
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2015-2026
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2015-2026
Figure 3.4 Keytruda Forecast, Revenue ($bn), 2015-2026
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2014
Figure 3.6 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2015
Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2014
Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2015-2026
Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2015
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2020
Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2026
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2014
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2026
Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.6 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2014
Figure 5.7 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2014-2025
Figure 5.8 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.9 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.10 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.11 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.12 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.13 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.14 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 6.1 Atezolizumab Forecast: Revenue ($bn), 2016-2026
Figure 6.2 Durvalumab Forecast: Revenue ($bn), 2016-2026
Figure 6.3 Avelumab Forecast: Revenue ($bn), 2017-2026
Figure 6.4 Tremelimumab Forecast: Revenue ($bn), 2016-2026
Figure 9.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2016, 2020, and 2026
Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2016, 2020, and 2026

【レポートのキーワード】

がん治療、チェックポイント阻害薬、CTLA-4阻害薬、PD-1阻害薬